Investigational drug · Phase 3
HDM1002
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Type 2 Diabetes, Overweight and Obesity.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 25, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
3 still active
All registered trials
13
Any phase or sponsor naming "HDM1002"
First trial start
2024
Jun 27, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HDM1002", any sponsor or status.
Conditions studied
As listed on its trial records.
- Type 2 Diabetes
- Overweight and Obesity
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "HDM1002" as an intervention, largest first.
- A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes MellitusPivotal-lookingRecruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT07082114 · 800 participants (planned) · Start Jul 14, 2025 · Primary completion Feb 16, 2027
Drug: HDM1002 100 mg; HDM1002 200 mg and 2 more · For: Type 2 Diabetes
Sites: Yueyang, China
- Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese AdultsPivotal-lookingNot yet recruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT06885021 · 780 participants (planned) · Start Mar 28, 2025 · Primary completion May 30, 2026
Drug: HDM1002 200mg, oral, once daily, 52 weeks; HDM1002 400mg, oral, once daily, 52 weeks and 1 more · For: Overweight and Obesity
- Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes MellitusPivotal-lookingRecruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT07193459 · 360 participants (planned) · Start Aug 12, 2025 · Primary completion Oct 10, 2026
Drug: HDM1002 200 mg; HDM1002 400 mg and 1 more · For: Type 2 Diabetes
Sites: Beijing, China
- To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes MellitusPivotal-lookingCompleted
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT06481085 · 324 participants · Start Jun 27, 2024 · Primary completion May 30, 2025
Drug: HDM1002 50 mg; HDM1002 100 mg and 4 more · For: Type 2 Diabetes
Sites: Beijing, China; Cangzhou, China; Changchun, China · 31 sites in all
- Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese AdultsPivotal-lookingStatus unknown
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT06500299 · 180 participants (planned) · Start Jul 15, 2024 · Primary completion Oct 30, 2024
Drug: HDM1002 100 mg QD; HDM1002 200 mg QD 12weeks and 2 more · For: Overweight and Obesity
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT07331389 · 111 participants (planned) · Start Sep 24, 2025 · Primary completion Jan 12, 2026
Drug: Metformin; Empagliflozin and 4 more · For: Overweight Subject; Healthy Subjects
Sites: Hefei, China
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT07594847 · 72 participants (planned) · Start Mar 7, 2026 · Primary completion Sep 25, 2026
Drug: HDM1002 200 mg; HDM1002 400 mg and 2 more · For: Healthy Adult Subject
Sites: Zibo, China
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT06520540 · 72 participants (planned) · Start Jul 28, 2024 · Primary completion Nov 30, 2024
Drug: HDM1002 100 mg QD 12weeks; HDM1002 200 mg QD 12weeks and 2 more · For: Glucagon-Like Peptide-1 Receptor Agonists
Sites: Shanghai, China
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT06985615 · 40 participants (planned) · Start Mar 18, 2025 · Primary completion Jan 14, 2026
Drug: Single dose of HDM1002 on Day 1 · For: Hepatic Impairment; Healthy Volunteers
Sites: Suzhou, China
- A Drug-Drug Interaction (DDI) Study of HDM1002 With Rifampicin and Itraconazole in Healthy SubjectsStatus unknown
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT06562088 · 40 participants (planned) · Start Aug 16, 2024 · Primary completion Nov 19, 2024
Drug: HDM1002 and rifampicin; HDM1002 and itraconazole · For: Healthy Adult Subject
Sites: Hefei, China
Newest research
PubMed records naming it or its code names, newest first.
- Pharmacokinetics and Food Effect of HDM1002, a Novel Oral Small-Molecule GLP-1 Receptor Agonist, in Healthy Chinese Volunteers: A Bioequivalence Study.
Huang C, Ying Y, Wu Y, et al. · Diabetes Obes Metab 2026
- HDM1002 in Chinese Adults With Overweight/Obesity: A Randomized, Placebo-Controlled, Ascending-Dose Phase 1b Study.
Xu H, Hu W, Zhao L, et al. · Obesity (Silver Spring) 2026
- First-in-human study of HDM1002, a GLP-1 receptor agonist: Safety, tolerability, pharmacokinetics and pharmacodynamics of escalating single oral doses in healthy volunteers.
Pu J, Huang Y, Wan L, et al. · Diabetes Obes Metab 2025
Also in development for Type 2 Diabetes
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- ZenagamtidePhase 39 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- OlatorepatideHS-20094Phase 38 trials
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Type 2 Diabetes, Overweight or Obesity, Overweight or Obesity Without Diabetes
- CagriSemaCagrilintide B and Semaglutide IPhase 36 trials
Novo Nordisk · Obesity, Diabetes Mellitus, Type 2, Hypertension
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.